Vir Biotechnology's recent share price rally is driven by their promising cancer program, despite their primary focus on hepatitis management. The company's market cap has surged past $1 billion, ...
SAN FRANCISCO, October 09, 2025--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in Part 3 of the Company’s Phase 1 clinical trial ...
Phase 1 clinical trial designed to assess the safety, pharmacokinetics and preliminary efficacy of VIR-5525 alone or in combination with pembrolizumab in a variety of EGFR-expressing solid tumors such ...
– Compelling early clinical response signals for VIR-5818 and VIR-5500 in heavily pretreated patients with various solid tumors VIR-5818: In patients receiving doses ≥400 µg/kg, tumor shrinkage ...
Shares of Vir Biotechnology (CIR) climbed ~42% in the premarket on Wednesday after the company posted initial Phase 1 data for two antitumor agents developed using its PRO-XTEN masking technology, ...
- Phase 3 ECLIPSE registrational clinical program in chronic hepatitis delta on track to begin in the first half of 2025 - Tobevibart and elebsiran in chronic hepatitis delta received U.S. FDA ...
CEO Marianne De Backer highlighted the completion of enrollment in ECLIPSE 1, Vir’s first registrational Phase III study for hepatitis delta, ahead of internal projections. She indicated that "we now ...
SAN FRANCISCO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, announced ...
Vir Biotechnology, Inc. (NASDAQ:VIR), currently trading at $5.02, has seen its stock decline over 34% year-to-date, reflecting investor concerns despite its potential in treating serious infectious ...
Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for ...
SAN FRANCISCO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback